IXICO expands Assessa PML platform pilot to include pharmacovigilance
The Assessa PML platform is designed to facilitate the remote transfer, management and storage of MRI scans to help doctors detect progressive multifocal leukoencephalopathy
Company
Biogen Inc
NASDAQ:BIIB
Biogen Inc is a leading global biotechnology company that has pioneered multiple breakthrough innovations including a broad portfolio of medicines to treat multiple sclerosis, the first approved treatment for spinal muscular atrophy, and two co-developed treatments to address a defining pathology of Alzheimer’s disease, the first treatment to target a genetic form of ALS, the first oral treatment approved for postpartum depression, and the first approved treatment for Friedreich’s ataxia.
60 stories · page 3 of 3
US stocks give back early gains to close lower on healthcare scare
US equities fell on Thursday, as initially buoyant stocks came off on the back of falls by utilities and a budgetary shock for the healthcare sector
Forward Pharma shoots up after US$1.25bn Biogen licensing deal
Biogen has agreed to pay US$1.25bn in cash to licence all of Forward’s intellectual property
Biogen boosts Alzheimer's hope with trial data
Gradually increasing the dose rather than starting at a high level appeared to cause less risk of brain swelling
US stocks close Friday with record highs as Trump rally rolls on
Wall Street stocks finished the week with another round of record highs as the sharp rally triggered by Donald Trump’s surprise presidential victory showed no signs of easing
Biogen and Ionis Pharma surge as Spinraza stars in trial
Motor function of children affected with spinal muscular atrophy (SMA) improved significantly
GW Pharma still has the legs to get over a tenner, but pick your entry point
Ideally you are looking at dips to the 50-day line at £6.29 - Zak Mir.
GW Pharmaceuticals data the "most convincing so far", says City heavyweight
Earlier this month investors were put on bid alert after a report suggest the company had multiple potential suitors.
Biogen completes FDA application for muscle wasting drug
Biogen also plans to submit a Marketing Authorization Application to the European Medicines Agency.
Morgan Stanley hired for GW Pharmaceuticals bid parade
Analysts say the drug has the potential to deliver annual sales of around US$800mln.
Mylan boss take the fight to Hillary
Mylan reacted by announcing plans to boost access to the product by expanding already-existing programs for patients who face what’s called out-of-pocket expenses.
Shire leads the fallers as £3.7bn is wiped from drugs sector after Clinton blast
Hilary Clinton took aim at one US drugs company - yet the shock waves were felt here in London.
Biogen tops Wall Street estimates for quarter
Biogen shares gain nearly 5% after the company beats estimates with its first quarter earnings
Wall Street shares seen higher with spotlight on earnings
Wall Street shares are seen opening slightly higher with earnings again in focus and after US markets closed up on Wednesday.
Biogen surges as fourth-quarter results top estimates
Results were helped by sales of the company’s most important multiple sclerosis drug, Tecfidera
Wednesday’s trending – Apple, oil and biotech
There were some big names taking a hit on Wednesday shedding light on the state of the global economy and none bigger than Apple...
Wall Street slides as biotech, commodities weigh; Biogen, TripAdvisor sink
U.S. stock indexes fell Friday as investors dumped shares of biotechnology companies after disappointing results from Biogen and as materials and energy stocks continued to lag. The S&P 500 (INDEXSP:.INX) slid 1.1 percent to 2,077.95 at
Wall Street poised to halt 3-day rout on strong earnings from Amazon, Visa, Starbucks
U.S. stock-index futures rose today after three straight days of losses as Amazon, Visa and Starbucks beat expectations. Nasdaq-100 futures rose 0.2 percent to 4,629. S&P 500 futures edged up 0.1 percent to 2,100, while those for the Do
Concerns over next phase of Niogen's Alzheimer candidate putting pressure on share price
Now, Cowen analyst Mark Schmidt, who set a price target for Biogen in the range of US$425-US$500 because of the Phase 1b’s results’ success, recently noted that as impressive as those results were the 6mg cohort "had not yet dif